Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Vemurafenib

Catalog No: tcsc0216

Available Sizes

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Size: 10g

Specifications

CAS No:
918504-65-1

Formula:
$C_{23}H_{18}ClF_2N_3O_3S$

Pathway:
MAPK/ERK Pathway;Autophagy

Target:
Raf;Autophagy

Purity / Grade:
>98%

Solubility:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

DMSO : 6.2 mg/mL (12.66 mM; Need ultrasonic and warming)

Alternative Names:
RG7204;RO5185426;PLX4032

Observed Molecular Weight:
489.92

Product Description

Vemurafenib (RG7204; PLX4032) is a novel and potent inhibitor of **B-RAF** kinase, with **IC_{50}**s of 31 and 48 nM for RAF^{V600E} and c-RAF-1, respectively.

IC50 & Target: IC50: 31 nM ($BRAF^{V600E}$), 48 nM (c-RAF-1)

In Vitro: Vemurafenib (PLX4032) selectively blocks the RAF/MEK/ERK pathway in BRAF mutant cells[1]. RG7204 is a potent inhibitor of proliferation in those expressing RAF^{V600E} but not $BRAF^{WT}$ in 17 melanoma cell lines. Vemurafenib (RG7204) induces MEK and ERK phosphorylation at high concentrations in CHL-1 cells[2]. Ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032[3].

In Vivo: Vemurafenib (PLX4032, 20, 25, 75 mg/kg, p.o.) causes dose-dependent inhibition of tumor growth, with higher exposures resulting in tumor regression of BRAF mutant xenografts[1]. RG7204 (12.5, 25, and 75 mg/kg, p.o.) significantly inhibits tumor growth and induced tumor regression in mice bearing LOX tumor xenografts[2].